Marshall Fordyce - Sep 13, 2022 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
President and CEO, Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
Sep 13, 2022
Transactions value $
-$408,455
Form type
4
Date filed
9/14/2022, 04:12 PM
Previous filing
Sep 13, 2022
Next filing
Oct 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $29.4K +10.2K +5.61% $2.90* 191K Sep 13, 2022 Direct
transaction VERA Class A Common Stock Sale -$211K -10.2K -5.31% $20.78 181K Sep 13, 2022 Direct F1, F2
transaction VERA Class A Common Stock Options Exercise $35.3K +12.2K +6.73% $2.90* 193K Sep 13, 2022 Direct
transaction VERA Class A Common Stock Sale -$262K -12.2K -6.31% $21.48 181K Sep 13, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -22.4K -2.23% $0.00 979K Sep 13, 2022 Class A Common Stock 22.4K $2.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022.
F2 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.12 to $21.11, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.13 to $22.05, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.